Zinc therapy of Wilson's disease: Two views by Brewer, George J. & Scheinberg, I. Herbert
Vol. 6 ,  No. 5, 1986 HEPATOI,O(;Y ELSEWHERE 1047 
3.  Chaussy C, Schmiedt E, Jocham D, et al. Extracorporeal shock- 
wave lithotripsy (ESWL) fix treatment o f  urolithiasis. IJrolop 
1984; 2359-66. 
4. Drach GW, Dretler S, Fair W. et al. Report o f the  United States 
Cooperative Study of extracorporeal shock-wave lithotripsy. .J Urol 
1986; 135:1127-113:3. 
,i. Ychoenfield LJ, Lachin JM, et al. ('henodiol (chenodeoxycholic 
acid) for dissolution of gallstones: The National Cooperative Gall- 
stones Study: a controlled trial of efficacv and safety. Ann Intern 
Med 1981; 95257-282. 
6. Erlinger S, Le Go A. Husson dM, et al. Franco-Belgian cooperative 
study of ursodeoxycholir acid in  the medical dissolution of gall- 
stones: a double-blind, randomized, dose-response study, and com- 
parison with chenodeoxycholir acid. Hepatology 1984; 4308-314. 
7. Allen Md, Borody TJ.  Bugliosi TF ,  et al. Rapid dmolution of 
gallstones by methyl tert-butyl ether: preliminary observations. N 
Engl J Med 1985: :112:217-220. 
8. Charig CR, Webb DR, Payne SR, et al. Comparison of treat.ment 
of' renal calculi by open surgery, percutaneous nephrolithotomy. 
and extracorporeal shockwave lithotripsy. Br J Med 1986: 292:877- 
879. 
ZINC THERAPY OF WILSON'S DISEASE: 
TWO VIEWS 
Van Caillie-Bertrand M,  Degenhart HJ,  Visser HKA, 
Sinausappel M and Bouquet J.  Oral zinc sulphate for 
Wilson's disease. Arch. Dis. Child. 1985; 60:656-659. 
ABSTRACT 
After initial promotion of copper excretion with 
D-penicillamine, the effect of oral zinc sulphate (3 
x 150 mg/day, loading dose; 3 x 100 mg/day, 
maintenance dose) in two children with clinically 
stable Wilson's disease was evaluated after com- 
pletion of three years' treatment. The course, 
judged by clinical, biochemical, and histological 
parameters was satisfactory in both. The urinary 
copper concentration reverted to less than 1.26 
~mo1/24 hours; and the serum copper concentra- 
tion decreased further during zinc sulphate treat- 
ment. In one child the rise in 24 hour urinary 
copper excretion observed after a challenge dose 
of D-penicillamine (220 mg/kg) remained constant 
throughout the period of observation while the 
liver copper content fell from 1460 pg/g dry 
weight to 890 pg/g dry weight. In the other patient, 
however, the liver copper content as well as the 
24 hour urinary copper excretion increased after 
D-penicillamine challenge during the third year of 
treat men t . 
We conclude that zinc sulphate is a low toxic and 
well tolerated alternative for D-penicillamine. The 
dosage depends, however, on individual factors 
not yet well understood, and we recommend re- 
striction of its use to patients who do not tolerate 
mpenicillamine well. We suggest monitoring of 
treatment with yearly D-penicillamine challenge 
and a liver biopsy if liver function deteriorates. 
COMMENTS 
The authors report clinically satisfactory control of 
Wilson's disease in two children on zinc sulfate therapy 
for 3 years each, but raise concerns about an increasing 
hepatic copper in one patient. This patient also showed 
an increasing urinary copper response to penicillamine 
challenge. Based on only these two patients, who were 
given a low dose of zinc which they took with food, the 
authors then develop rather sweeping conclusions that 
the dosage of zinc depends on individual factors not well 
understood, and that zinc should be restricted to patients 
not tolerating penicillamine. 
Our own experience is based on 39 patients treated 
with zinc, the longest for 5 years, with an average of 
about 2.5 years (1-4). Our standard dose is 50 mg ele- 
mental zinc (as the acetate salt) taken three times per 
day, avoiding food by an hour before and after each dose. 
In contrast, the authors used about 23 mg elemental zinc 
(as the sulfate) three times per day, taken with meals. 
This dose is lower than has been proven adequate by 
either ourselves or the Hoogenraad Group (5), who have 
also been using zinc for the maintenance therapy of 
Wilson's disease. However, my main criticism of the 
authors zinc regimen is that they gave the zinc with food. 
We (6) and others (7) have shown that this greatly 
reduces zinc's effectiveness. The use of the acetate salt 
makes it feasible to give zinc in the absence of food, since 
it causes much less gastric irritation than the sulfate 
salt. 
The authors monitored efficacy by evaluating control 
of symptoms, liver function tests, serum copper, urine 
copper levels in the absence and presence of penicilla- 
mine, hepatic copper levels and morphology and an IVM 
copper 64Cu procedure. We monitor efficacy by most of 
these techniques (no IV "Cu procedure) plus copper 
balance, "Cu uptake into blood after an oral dose, level 
of nonceruloplasmin plasma copper, slit lamp exam, 
quantitative neurological exam and a variety of other 
specialized examinations. Copper balance is a research 
procedure and is thus not feasible in the usual clinical 
setting, but it is the standard by which we have validated 
the other monitoring procedures. uptake is very 
useful because the mechanism of zinc action is blockade 
of intestinal uptake of copper, and with a fully effective 
dose of zinc, the blood "Cu peak will be less than 1% of 
the administered dose (4). We have found the 24-hr 
urinary excretion of copper to be more useful than urine 
copper after penicillamine challenge. In the absence of 
penicillamine treatment, the urinary excretion of copper 
reflects the body load of excess copper much as glycosuria 
reflects excess glucose in a diabetic patient. In well- 
decoppered patients, this value should be below 100 p 
per 24 hr. Trends upward over time suggest inadequate 
control. Measuring the copper in urine accurately, par- 
ticularly in the normal or near-normal range, requires a 
good atomic absorption spectrophotometer. (We use an 
Instrumentation Laboratory Model 451, which even in 
the flame mode has this capability.) The problems with 
using the penicillamine challenge procedure to monitor 
patients on zinc includes the variability of this procedure, 
but more importantly we have seen the values go down- 
ward over time in patients who were well decoppered in 
the first place while all other parameters indicate no 
change in copper status. We suspect that in zinc-loaded 
patients, zinc competes with copper for binding to the 
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penicillamine. Stopping zinc even for 2 weeks prior to 
the test has not remedied this problem. 
Another simple and useful variable to follow is the 
nonceruloplasmin plasma copper. If one subtracts the 
ceruloplasmin copper from total plasma copper, one ob- 
tains the value for the potentially toxic copper. We like 
to see this value kept below 25 pg per dl. Trends upward 
suggest loss of control. Hepatic copper as assessed by 
biopsy is a method for evaluating control of copper 
accumulation by anticopper therapy over a longer time 
span. Our experience in well-decoppered patients on zinc 
therapy is very good (Brewer, G. J. et al., Clin. Res. 1985; 
33:871A, Abstract). In 10 such patients biopsied at the 
beginning and after 12 to 20 months of therapy, no 
patient showed reaccumulation of hepatic copper (mean 
before was 218 pg per gm dry weight, while the after 
therapy mean was 200 pg per gm dry weight). 
Summarizing our efficacy experience with patients on 
a maintenance dose of 50 mg of zinc three times per day, 
we have seen excellent control of copper balance, hepatic 
copper levels, prevention of redevelopment of Kayser- 
Fleischer rings and no redevelopment of symptoms. On 
three occasions, we have noted increasing urinary copper 
and nonceruloplasmin plasma copper in particular pa- 
tients. In each case, we found a compliance problem with 
the patient taking the medication. 
My assessment of the authors results in these two 
patients is that the patients have done well considering 
the low dose and administration of zinc with meals. Both 
patients showed a reduction of total serum copper, which 
means, if ceruloplasmin levels did not change, that non- 
ceruloplasmin plasma copper came under good control. 
Urinary copper was also well controlled in both patients 
(except for one high value in both patients at about 3 
years). It is difficult to interpret the one unusually high 
penicillamine cupruresis value in Patient 2 because of 
the problem with this procedure already mentioned. The 
higher hepatic copper value in this same patient suggests 
the need for a rebiopsy. On two occasions, we have seen 
differences of 400 to 500 pg copper per gm dry weight 
from different liver biopsy samples from the same pa- 
tient, and rebiopsy in both cases confirmed one of the 
values, indicating that indeed the Wilson’s disease liver 
can on occasion by “patchy” with respect to copper. The 
addition of an oral 64Cu uptake procedure to this patient’s 
evaluation at this same point would have told us much 
about adequacy of control. 
Zinc acetate for the treatment of Wilson’s disease has 
been designated an orphan treatment by the U.S. FDA, 
and has been adopted for development by the Lemmon 
Company. We anticipate possible marketing (pending 
FDA approval) by 1987. The dose I recommend, at least 
for the present, is 50 mg of elemental zinc, three times 
per day, avoiding food by 1 hr. The minimal monitoring 
procedures for patients on maintenance therapy should 
include 24-hr urine copper, nonceruloplasmin plasma 
cooper, oral W u  uptake and appropriate clinical studies. 
Assessment of hepatic copper can also be used, but 
should not be necessary on a routine basis. Our present 
experience indicates that all Wilson’s disease patients 
can be safely maintained on zinc therapy, if they take an 
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COMMENTS 
Evaluating this paper, which concludes that zinc sul- 
fate is an alternative treatment to penicillamine in Wil- 
son’s disease, requires a comparison of the natural and 
pharmacologically modified histories of Wilson’s disease. 
Wilson’s disease represents chronic copper intoxica- 
tion in man, primarily affecting the liver and brain. It 
occurs only in individuals who inherit an abnormal pair 
of specific, autosomal, recessive genes. From 1912, when 
Wilson first described the syndrome (1) through 1956, 
when Walshe suggested that D-penicillamine might be 
effective therapy (2), the disease was always fatal. Pa- 
tients died of either hepatic or cerebral involvement, 
usually after torturous years of hepatic, neurologic and 
psychiatric symptoms. Unlike most inborn errors of me- 
tabolism, symptoms of the disease never appear before 6 
years of age, are unusual before adolescence, and, rarely, 
do not appear for more than 40 years (3). 
Penicillamine, the dimethyl derivative of cysteine, rev- 
olutionized the treatment and course of this disease. 
Severely ill patients were often restored to completely 
normal health. Patients in whom the diagnosis of Wil- 
son’s disease was made while they were still asympto- 
matic remained so indefinitely if they continuously took 
1 gm or so of penicillamine daily. 
Furthermore, penicillamine was not very toxic. In our 
personal experience, a toxic reaction requiring with- 
drawal of penicillamine, most commonly for proteinuria, 
occurred in about 5% of patients. For such patients 
triethylene tetramine dihydrochloride (Trien@ or Cu- 
prid“), also introduced by Walshe in 1970, has proven to 
be as effective therapeutically as penicillamine (4). 
Trien“’ was approved for Wilson’s disease by FDA in 
1985. 
The paper of Caillie-Bertrand et al. provides little 
justification for the therapeutic use of zinc in Wilson’s 
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disease. Indeed, there was no apparent clinical indication 
for its use in the two asymptomatic children with the 
disease that they report. Both were "clinically stable" 
with no indication of toxicity to penicillamine after 1 
and 3 years of treatment, respectively. Apparently, there 
were no changes in their clinical condition during 3 years 
of zinc treatment. Both were asymptomatic when zinc 
was started and might well have remained so for years 
without any treatment. Although zinc treatment was 
accompanied by a fall in hepatic copper concentration of 
one patient, from 1,460 p g  per gm dry weight to 890, that 
of the other rose from 350 to 1,050 pg per gm dry weight. 
This is faint praise. 
It is well established that zinc, usually in about twice 
the dosage used by these authors, can inhibit the gas- 
trointestinal absorption of copper (5). It has as yet not 
been shown that this action is accompanied by a decrease 
in the copper concentrations of either the liver or the 
brain. 
A controlled double-blind study of the therapeutic role 
of zinc in Wilson's disease can almost certainly not now 
be performed. It is difficult to see how a patient with an 
unequivocal diagnosis of this lethal disorder can ethically 
be denied treatment with penicillamine or Trien"' for the 
length of time necessary to determine whether zinc ther- 
apy is effective. If the patient is asymptomatic, and 
remains so, how and when can one conclude that zinc 
was beneficial? Whether asymptomatic or symptomatic, 
particularly in the presence of hepatic dysfunction, the 
escalation of the disease to fulminant hepatitis is usually 
irreversible and is often rapidly fatal. 
These authors classify zinc as being of low toxicity. 
Both copper and zinc are essential, heavy metals of 
virtually identical atomic weight which are present in 
trace quantities in metalloproteins and enzymes almost 
exclusively as prosthetic elements. Since the two metals 
are so much alike chemically, and biologically, and since 
it is known that copper is toxic, can it be assumed that 
years of administering zinc in ten or more times the daily 
nutritional requirement, the zinc will be nontoxic, or 
only minimally so? 
Except for the patient with Wilson's disease who has 
had no beneficial response to a long course of penicilla- 
mine therapy or a significant, irreversible reaction to 
both penicillamine and Trien'"', zinc has no place in the 
treatment of Wilson's disease. Readers who question this 
recommendation should ask themselves how they would 
want their own children with Wilson's disease to be 
treated. 
I. HERBERT SCHEINBERG, M.D. 
Albert Einstein College of Medicine 
Bronx. New York 10461 
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MEMBRANE POTENTIAL AND HEPATIC 
UPTAKE: ANOTHER RULE OF THE GAME 
Edmondson JW, Miller BA and Lumeng L. Effect of 
glucagon on hepatic taurocholate uptake: relationship to 
membrane potential. Am. J. Physiol. 1985; 249 
(Gastrointest. Liver Physiol. 12):G427-G433. 
ABSTRACT 
Since glucagon can hyperpolarize hepatic 
plasma membrane and stimulate biliary bile acid 
secretion in vitro, we studied the effect of glucagon 
on taurocholate uptake and its relationship to 
plasma membrane potential in isolated rat hepa- 
tocytes. [ ''C]Taurocholate uptake was linear 
through 1 min and contained a saturable sodium- 
dependent and a nonsaturable sodium-independ- 
ent component, K, of taurocholate uptake by the 
sodium-dependent system was 18.4 pM. Hill coef- 
ficient for Na+ was 2.59 and for taurocholate was 
1.1, suggesting that the stoichiometry is 2 Na+:l 
bile acid. Stimulation of taurocholate uptake by 
glucagon was limited to the sodium-dependent 
component, detected within 5 min of hormone ex- 
posure, and was maximum at 30 min. Glucagon, 
from lo-' to lo-' M, stimulated taurocholate up- 
take and hyperpolarized concurrently the plasma 
membrane potential. Because valinomycin pro- 
duced a dose-related depolarization of plasma 
membrane potential, this agent was used to coun- 
teract the effects of glucagon. With lo4 M gluca- 
gon, valinomycin (10-l' M) depolarized membrane 
potential from -35.50 to -28.00 mV and inhibited 
taurocholate uptake from 60% above the control 
rate to 5% below. These data strongly suggest that 
taurocholate uptake by isolated hepatocytes is an 
electrogenic process, and its stimulation by gluca- 
gon may be mediated by changes in plasma mem- 
brane potential. 
COMMENTS 
The complex process by which liver takes up, stores 
and excretes into the bile exogenous and endogenous 
compounds has been addressed in the past by several 
investigators. Bile acids are a composite class of sub- 
stances with several important characteristics. One of 
the critical steps in their metabolism is the uptake oc- 
curring at the sinusoidal-basolateral plasma membrane. 
In spite of the large number of investigations which deal 
with bile acids, some of the key issues in their metabolism 
are still unclear. Among these is the point Edmundson 
and coworkers address in this article, i.e., does the uptake 
process of taurocholate occur electrogenically? In this 
investigation, freshly isolated rat hepatocytes were meas- 
ured for taurocholate uptake after modification of the 
